Domov › Ulcerativni kolitis › Maryland
Klinične študije za Ulcerativni kolitis v Maryland
13 študij za Ulcerativni kolitis išče udeležence na lokacijah v Maryland.
Mesta v Maryland
Uradno besedilo študije (angleško)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
Vključevanje udeležencevOpazovalna študija
Starost 18–85 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07619547A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06581328A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 011, Glen Burnie
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07012395Immune Regulation in Ulcerative Colitis or Crohn s Disease
- National Institutes of Health Clinical Center, Bethesda
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
1 Day – 75 Years · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT00001184A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
Vključevanje udeležencevFaza 3
Starost 12 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Capital Digestive Care - Chevy Chase, Chevy Chase
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase
Vključevanje udeležencevFaza 4
Starost 18–65 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06095128An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Mercy Medical Center, Baltimore - Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC - Site Number: 8400106, Greenbelt
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT07184996Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates PA, Glen Burnie
Vključevanje udeležencevOpazovalna študija
Starost 18–64 · Vsi spoli · Posodobljeno 9. jul. 2026 · NCT06398626A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 22. maj 2026 · NCT06764615Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Capital Digestive Care, Chevy Chase
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 8. maj 2025 · NCT06750731Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.